J&J builds case for antidepressant Spravato with head-to-hea...

Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to ac

Axsome bounces back as FDA clears depression drug

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was

After a nay from NICE, Scotland says aye to J&J’s Spravato

NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug that has been turned down twice by NICE for patients in England.

NICE rejects Janssen's depression spray Spravato for second ...

NICE has rejected regular NHS funding for Janssen’s depression spray Spravato (esketamine) for a second time, although the company says it could salvage the situation by providing further d

NICE rejects J&J’s Spravato for treatment-resistant depressi...

J&J seeks wider use of its Spravato antidepressant in US